, 2022 Introduction: Measurement of fibroblast growth factor 23 (FGF23) has been reported to be clinically useful for the differential diagnosis of chronic hypophosphatemia. However, assays for research use only are available in Japan.
Adachi, Masanori +13 more
core
Efficacy and safety of burosumab in X-linked hypophosphataemia: Systematic review and meta-analysis [PDF]
, 2022 Sen Wang +5 more
openalex +1 more source
A PAI‐1 antagonist ameliorates hypophosphatemia in the Hyp vitamin D‐resistant rickets model mouse
FEBS Open Bio, Volume 14, Issue 2, Page 290-299, February 2024.Plasminogen activator inhibitor‐1 (PAI‐1) antagonists activate tPA and Furin to degrade fibroblast growth factor 23 (FGF23). We examined TM5614, a PAI‐1 antagonist, as a potential therapeutic agent for FGF23‐associated hypophosphatemic rickets. Oral administration of TM5614 to Hyp mice, an X‐linked hypophosphatemia (XLH) model, caused normalization of ...
Cheng Qian +7 more
wiley +1 more source
The use of immunobiological monoclonal antibody-based drugs in nephrological practice
Počki, 2018 При різних захворюваннях нирок успішно застосовується імунобіологічна терапія на основі моноклональних антитіл із різним механізмом дії. До таких лікарських засобів належать: ритуксимаб (взаємодія з рецептором CD20 і елімінування В-клітин), екулізумаб ...
O.O. Melnyk
doaj +1 more source
X-linked hypophosphatemic rickets. What the orthopedic surgeon needs to know [PDF]
, 2021 Purpose: X-linked hypophosphatemic rickets (XLH) is a rare genetic disease characterized by an increase in fibroblast growth factor 23 (FGF23) expression.
Adriano Braile +7 more
core
Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review [PDF]
, 2022 Claudia Maria Jurca +8 more
openalex +1 more source
Potential predictors of response to burosumab treatment in adult patients with X-Linked Hypophosphatemia [PDF]
Background: X-linked hypophosphatemia (XLH) is a rare genetic condition characterized by elevated FGF23 levels, leading to chronic renal phosphate loss and persistent hypophosphatemia, which results in both skeletal and extraskeletal abnormalities ...
ARCIDIACONO, GAETANO PARIDE
core
MO037: Burosumab in adult patients with X-linked hyphophosphatemic rickets: an Italian Experience [PDF]
, 2022 Nadia Edvige Foligno +6 more
openalex +1 more source
PCR31 Assessment of Pain, Stiffness, and Physical Functioning Pre and During Burosumab Among Adults with X-Linked Hypophosphatemia: Results from a Multinational, Long-Term, Prospective Outcomes Disease Monitoring Program [PDF]
, 2023 Edward Yang +4 more
openalex +1 more source